AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14724106
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (100 U/kg x b.w. intravenous bolus, 1,000 U/h continuous infusion for 3 days, then subcutaneous 7500 U every 12 h for 4 days, n=90)
Trial: 11759189
Drug: Oral montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast (n = 83)
Trial: 11759189
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone 100 mcg three times daily (n = 41)
Trial: 17532829
Drug: Oral montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast
Trial: 3377519
Drug: Conventional dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dry gauze dressing (Curity) and antibiotic ointment (Polysporin)
Trial: 23280675
Drug: Nicabate CQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicabate CQ Nicotine Replacement therapy (NRT)
Trial: 21593301
Drug: Insulin targeting
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin targeting postprandial glycemia
Trial: 21593301
Drug: Insulin targeting
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin targeting fasting/premeal glycemia
Trial: 18283509
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment (2,940 nm) with variable pulse durations (1 ms to 2 ms) and energy densities (800 mJ/cm(2) to 1,400 mJ/cm(2)), 4 to 8 passes, single session
Trial: 16488800
Drug: Facilitated PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated PCI with full-dose tenecteplase (n=829)
Trial: 16488800
Drug: Facilitated PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated PCI with full-dose tenecteplase
Trial: 14504416
Drug: Gabapentin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (300 mg initial dose, mean dosage 800 +/- 397 mg, range 300-1200 mg)
Trial: 14504416
Drug: Ropinirole (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole (0.5 mg initial dose, mean dosage 0.78 +/- 0.47 mg, range 0.25-1.50 mg)
Trial: 9165958
Drug: Midazolam 0.5
RxNorm normalized name: midazolam 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.5 mg.kg‐1 given 30 min pre-operatively
Trial: 9165958
Drug: Trimeprazine 2
RxNorm normalized name: trimeprazine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimeprazine 2 mg.kg‐1 given 90 min pre-operatively
Trial: 8238827
Drug: Increased fresh
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased fresh gas flow from 40 to 120 ml.kg‐1 x min‐1 (Group 1)
Trial: 28108224
Drug: Elcatonin monotherapy
RxNorm normalized name: elcatonin
DrugBank: Elcatonin (DB13742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elcatonin monotherapy (20 units weekly)
Trial: 28108224
Drug: Minodronic acid
RxNorm normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Minodronic acid hydrate monotherapy (1 mg daily)
Trial: 28108224
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (elcatonin and minodronic acid hydrate)
Trial: 16825268
Drug: 10 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/day bovine colostrum protein concentrate (CPC)
Trial: 16825268
Drug: 10 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/day whey protein (placebo)
Trial: 8216665
Drug: Topical lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lignocaine 4 mg/kg (group A)
Trial: 8216665
Drug: Rectal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal paracetamol 10 mg/kg (group B)
Trial: 28481726
Drug: RV3-BB vaccine
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RV3-BB vaccine (neonatal schedule)
Trial: 28481726
Drug: RV3-BB vaccine
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RV3-BB vaccine (infant schedule)
Trial: 29906071
Drug: Cashew apple
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cashew apple juice (240 mg/day)
Trial: 29906071
Drug: Cashew apple
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cashew apple juice (120 mg/day)
Trial: 18928091
Drug: Chinese herbs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbs for supplementing Shen, orally administered three days before and after ESWL
Trial: 15946284
Drug: Oral cryotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cryotherapy using ice cubes before and during chemotherapy infusions.
Trial: 8154822
Drug: Acute perioperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute perioperative normovolaemic haemodilution with retransfusion of autologous blood (900 ml taken preoperatively, replaced with 1000 ml of gelatin solution)
Trial: 2484360
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 supplementation (2 mg daily)
Trial: 29211857
Drug: Continued antiarrhythmic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued antiarrhythmic drug treatment (ADT ON)
Trial: 29211857
Drug: Discontinued antiarrhythmic
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued antiarrhythmic drug treatment (ADT OFF)
Trial: 28700482
Drug: Fu-Zheng-Qu-Zhuo oral
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fu-Zheng-Qu-Zhuo oral liquid (FZQZ)
Trial: 23816199
Drug: Aftercare services
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aftercare services including treatment follow-up (home care or telephone follow-up), family psychoeducation, and patient social skills training provided by community mental health teams.
Trial: 21714999
Drug: GAD‐alum (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD‐alum (20 μg, three injections)
Trial: 21714999
Drug: GAD‐alum plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD‐alum plus alum (20 μg GAD‐alum, two injections and one of alum)
Trial: 21714999
Drug: Alum (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum (three injections)
Trial: 9203944
Drug: Hyperglycaemia (16-19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (16-19 mmol/l glucose)
Trial: 9203944
Drug: Euglycaemia (5-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia (5-8 mmol/l glucose)
Trial: 7950736
Drug: Paracetamol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1 g twice daily)
Trial: 7950736
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drug (diclofenac 50 mg twice daily)
Trial: 3389899
Drug: Conventional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intravenous cannulae
Trial: 26742304
Drug: PCIA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCIA group (Ondansetron 8 mg IV for 5 min, tramadol 1.5 mg/kg infusion)
Trial: 26742304
Drug: PCEA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA group (Ropivacaine 3 mg intrathecal, epidural infusion of Ropivacaine 0.1% and Sufentanil 50 ug)
Trial: 2815966
Drug: Trivalent split
RxNorm normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent split virus vaccine
Trial: 2815966
Drug: Monovalent A/Taiwan/86(H1N1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent A/Taiwan/86(H1N1) vaccine
Trial: 31663462
Drug: Smart Pill
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smart Pill Bottle (SPB) with pharmacist intervention
Trial: 29354972
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of central‐square needling technique of thumb‐tack needles with routine therapy of acupuncture, moxibustion and tuina
Trial: 29354972
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy of acupuncture, moxibustion and tuina
Trial: 23242570
Drug: EMLA(®) cream
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA(®) cream (2.5 g applied for a minimum of 30 min before venipuncture)
Trial: 18362868
Drug: d‐MPH‐ER (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐MPH‐ER (20 mg/day)
Trial: 18362868
Drug: d,l‐MPH‐ER (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l‐MPH‐ER (36 mg/day)
Trial: 18362868
Drug: d‐MPH‐ER and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐MPH‐ER and d,l‐MPH‐ER
Trial: 16412546
Drug: High potency
RxNorm normalized name: High Potency B+C
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High potency neuroleptic agents (risperidone/ziprasidone/aripiprazole)
Trial: 16412546
Drug: Low potency
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low potency neuroleptic agents (quetiapine/olanzapine)
Trial: 12937308
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg) and clopidogrel (75 mg) daily
Trial: 11012555
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride 550 mg in solution alone
Trial: 11012555
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride 550 mg in solution after 10 mg i.v. dose of metoclopramide
Trial: 11012555
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride 550 mg in solution after 30 mg oral dose of propantheline
Trial: 8598838
Drug: Saquinavir (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir (1800 mg per day) plus zidovudine (600 mg per day) and zalcitabine (2.25 mg per day)
Trial: 8598838
Drug: Three-drug combination
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug combination (saquinavir, zidovudine, zalcitabine)
Trial: 1412099
Drug: Mask without
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mask without Venturi attachment at 2, 4, and 6 l/min
Trial: 1412099
Drug: Mask with
RxNorm normalized name: SULFUR 10 g in 100 mL TOPICAL CREAM [Soothing Antiseptic Mask with Sulfur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mask with Venturi attachments (24% and 28%) at 2 and 4 l/min
Trial: 6443774
Drug: Cefsulodin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefsulodin (various dosages, including 250 mg every 6 hr)
Trial: 11984383
Drug: Isopropyl alcohol
RxNorm normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isopropyl alcohol (IPA) inhalation
Trial: 26138593
Drug: Clazakizumab 25
RxNorm normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab 25 mg plus MTX
Trial: 26138593
Drug: Clazakizumab 100
RxNorm normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab 100 mg plus MTX
Trial: 26138593
Drug: Clazakizumab 200
RxNorm normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab 200 mg plus MTX
Trial: 26138593
Drug: Clazakizumab 100
RxNorm normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab 100 mg monotherapy
Trial: 26138593
Drug: Clazakizumab 200
RxNorm normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab 200 mg monotherapy
Trial: 26138593
Drug: All clazakizumab
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All clazakizumab groups (25 mg, 100 mg, 200 mg)
Trial: 26138593
Drug: Clazakizumab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab treatment groups
Trial: 11518061
Drug: WS 5570
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS 5570 Hypericum perforatum extract 300 mg
Trial: 11518061
Drug: WS 5570
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS 5570 Hypericum perforatum extract 600 mg
Trial: 29319408
Drug: Tremella fuciformis
RxNorm normalized name: TREMELLA FUCIFORMIS WHOLE
DrugBank: Tremella fuciformis whole (DB14359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremella fuciformis 600 mg/day, n=30
Trial: 29319408
Drug: Tremella fuciformis
RxNorm normalized name: TREMELLA FUCIFORMIS WHOLE
DrugBank: Tremella fuciformis whole (DB14359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremella fuciformis 1200 mg/day, n=30
Trial: 29319408
Drug: Tremella fuciformis
RxNorm normalized name: TREMELLA FUCIFORMIS WHOLE
DrugBank: Tremella fuciformis whole (DB14359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremella fuciformis (both doses combined)
Trial: 29319408
Drug: Tremella fuciformis
RxNorm normalized name: TREMELLA FUCIFORMIS WHOLE
DrugBank: Tremella fuciformis whole (DB14359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremella fuciformis (both doses)
Trial: 26571900
Drug: Shujing massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shujing massage therapy
Trial: 26571900
Drug: Medication with
RxNorm normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication with estazolam (1 mg orally before sleep)
Trial: 19064533
Drug: 10.2 mg
RxNorm normalized name: serine 10.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.2 mg ELTP/d in a yogurt beverage for 8 weeks
Trial: 12680883
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg intranasal mometasone furoate (MF) once daily for 2 weeks
Trial: 12680883
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg intranasal mometasone furoate (MF)
Trial: 7030372
Drug: Penbutolol, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol, 80 mg once a day
Trial: 7030372
Drug: Hydrochlorothiazide, 100
RxNorm normalized name: HydroCHLOROthiazide, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide, 100 mg once a day
Trial: 26064677
Drug: Caloric Titration
RxNorm normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caloric Titration Method (CTM)
Trial: 23914211
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 mg kg(‐1) for the first 10 min, followed by continuous infusion of dexmedetomidine (0.2‐0.7 μg kg(‐1) h(‐1))
Trial: 23914211
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg kg(‐1) h(‐1) for the first 10 min, followed by continuous infusion of midazolam (0.05‐0.15 μg kg(‐1) h(‐1))
Trial: 20233198
Drug: Prior administration
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior administration of terbutaline
Trial: 18802369
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluid therapy (specific types not detailed, e.g., hydroxyethylstarch)
Trial: 16482787
Drug: Subcutaneously-placed, round,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously-placed, round, saline-filled prosthesis with a textured surface (Siltex and Microcell implants)
Trial: 16482787
Drug: Reoperation for
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reoperation for capsular contracture (open capsulotomy with or without implant exchange, closed compression capsulotomy)
Trial: 16482787
Drug: Large-pore implants
RxNorm normalized name: Oxy Deep Pore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-pore implants
Trial: 12672710
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral calcium load with serum 25OHD at 86.5 nmol/L
Trial: 12672710
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral calcium load with serum 25OHD at 50 nmol/L
Trial: 10819857
Drug: Atosiban (6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (6.75 mg intravenous bolus, 300 microg/min for 3 hours, then 100 microg/min intravenously)
Trial: 10819857
Drug: Ritodrine (0.10‐0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritodrine (0.10‐0.35 mg/min intravenously)
Trial: 1869345
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation (sulpiride 200 mg)
Trial: 1869345
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (sulpiride 200 mg)
Trial: 3160869
Drug: High-dose medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medroxyprogesterone acetate (HD-MPA) 1200 mg p.o., b.i.d.
Trial: 3160869
Drug: High-dose medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medroxyprogesterone acetate (HD-MPA)
Trial: 24325365
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) formulation, 100 mg administered three times at 6-h intervals
Trial: 24325365
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) formulation, 300 mg administered once to fasting subjects
Trial: 24325365
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) formulation, 300 mg administered once to fed subjects
Trial: 21883710
Drug: Systemic antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotic therapy (n=10)
Trial: 21883710
Drug: No prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prior antibiotic therapy (n=10)
Trial: 18313905
Drug: Novel lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel lipid formulation containing fenofibrate in omega‐3 oil
Trial: 2880497
Drug: Beta-blocking drugs
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocking drugs
Trial: 7031855
Drug: Subunit influenza
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit influenza vaccine (A/Victoria/75 and B/Hongkong/73)
Trial: 27053642
Drug: Imitation-based speech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imitation-based speech therapy for 6 weeks
Trial: 24346608
Drug: Quetiapine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine with adjunctive personalized treatments (APTs)
Trial: 24346608
Drug: Lithium with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium with adjunctive personalized treatments (APTs)
Trial: 20171653
Drug: Montelukast (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (4 mg) for 3 months
Trial: 16366762
Drug: Isradipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (30 mg sustained release nightly plus 15 mg immediate release 2 hr before cocaine infusion)
Trial: 9218198
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of verapamil and trandolapril
Trial: 31959609
Drug: HEV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEV vaccine (HEV 239, Hecolin)
Trial: 14557958
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (hepatitis B vaccine)
Trial: 29215606
Drug: Nutrient enriched
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nutrient enriched breakfast bar (containing α‐Linolenic acid, l‐tyrosine, l‐theanine, vitamins, minerals and 21.5 mg of caffeine)